Efficacy And Safety Of CX516 In Elderly Participants With Mild Cognitive Impairment.
| Status: | Completed |
|---|---|
| Conditions: | Cognitive Studies |
| Therapuetic Areas: | Psychiatry / Psychology |
| Healthy: | No |
| Age Range: | 55 - 85 |
| Updated: | 7/25/2018 |
| Start Date: | April 2002 |
| End Date: | June 2004 |
Efficacy And Safety Of CX516 (900 mg t.i.d.) In Elderly Participants With Mild Cognitive Impairment. A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group 4-week Study.
Glutamate is fundamentally involved in learning and memory. Memory loss associated with mild
cognitive impairment may be due to loss of glutamate receptors in the aging brain. There is
evidence CX516 enhances brain activity by specifically targeting remaining glutamate
receptors in the affected portions of the brain. This study will test the safety and efficacy
of CX516 in the symptomatic treatment of participants with mild cognitive impairment.
cognitive impairment may be due to loss of glutamate receptors in the aging brain. There is
evidence CX516 enhances brain activity by specifically targeting remaining glutamate
receptors in the affected portions of the brain. This study will test the safety and efficacy
of CX516 in the symptomatic treatment of participants with mild cognitive impairment.
Inclusion criteria
- Clinical diagnosis of mild cognitive impairment
- Good general health with no additional diseases that would interfere with the study.
Exclusion criteria
- Any significant neurologic disease (other than suspected incipient Alzheimer's
disease), such as Parkinson's disease, stroke, TIA's, multi-infarct dementia,
Huntington's disease, head trauma, chronic CNS infection.
- History of major depression or another major psychiatric disorder within the past 6
months.
- History of schizophrenia, mania or recurrent psychotic episodes.
- History of alcohol or DSM IV-diagnosed substance abuse or dependence disorder within
the past year.
- History of blackout, epilepsy or seizures, or an abnormal EEG as judged by the
Investigator and considering the age of the participant.
- Any clinically significant hepatic, renal, cardiovascular, pulmonary, gastrointestinal
or hematological illness or unstable medical condition which could interfere with drug
safety, or absorption, distribution, metabolism and excretion, or lead to difficulty
complying with the protocol.
We found this trial at
8
sites
University of California, Irvine Since 1965, the University of California, Irvine has combined the strengths...
Click here to add this to my saved trials
University of California at Los Angeles The University of California, Los Angeles (UCLA) is an...
Click here to add this to my saved trials
University of Pittsburgh The University of Pittsburgh is a state-related research university, founded as the...
Click here to add this to my saved trials
Click here to add this to my saved trials
Yale University School of Medicine Founded in 1810, the Yale School of Medicine is a...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
13101 USF Sycamore Drive
Tampa, Florida 33617
Tampa, Florida 33617
Click here to add this to my saved trials